Endocrine News and Research

RSS

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Selective targeting of neurotransmitters may allow for new medication therapies for GI conditions

Selective targeting of the neurotransmitter that differentially affects brain cells that control the two distinct functions of the pancreas may allow for new medication therapies for conditions like diabetes, dyspepsia and gastro-esophageal reflux, according to Penn State College of Medicine researchers.

5 Dec 2012

Combined oral contraceptives increase risk of blood clots in women with PCOS

Women with polycystic ovary syndrome (PCOS) who are taking combined oral contraceptives have a 2-fold risk of blood clots compared with women without the disorder who take contraceptives, states a study published in CMAJ (Canadian Medical Association Journal).

4 Dec 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).

29 Nov 2012

Certain occupations do increase risk of breast cancer

Is there a link between the risk of breast cancer and the working environment? A study published in BioMed Central's open access journal Environmental Health provides further evidence on this previously neglected research topic, confirming that certain occupations do pose a higher risk of breast cancer than others, particularly those that expose the worker to potential carcinogens and endocrine disrupters.

19 Nov 2012

Cancer Network, ONCOLOGY present two part primer report on targeted therapies in solid tumors

UBM Medica US announces that Cancer Network and the journal ONCOLOGY are presenting a two part primer report on targeted therapies in solid tumors.

17 Nov 2012

In utero exposure to BPA associated with decreased thyroid function in newborn sheep

In utero exposure to bisphenol A (BPA) can be associated with decreased thyroid function in newborn sheep, according to a recent study accepted for publication in Endocrinology, a journal of The Endocrine Society. Hypothyroidism is characterized by poor mental and physical performance in human adults and in children can result in cognitive impairment and failure to grow normally.

15 Nov 2012

New study confirms neurodevelopmental effects of PBDE flame retardant exposure in children

Prenatal and childhood exposure to flame retardant compounds are linked to poorer attention, fine motor coordination and IQ in school-aged children, a finding by researchers at the University of California, Berkeley, that adds to growing health concerns over a chemical prevalent in U.S. households.

15 Nov 2012

Age at onset of first menstrual cycle associated with increased BMI, obesity in adulthood

Age at onset of menarche (first menstrual cycle) is associated with increased body mass index (BMI), waist circumference, and overall obesity in adulthood, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

15 Nov 2012

Hearing impairment more prevalent among patients with diabetes

Patients with diabetes have a significantly higher prevalence of hearing impairment than patients without diabetes, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Study authors note that the finding is likely to be independent of the effect of aging or a noisy environment.

14 Nov 2012

Diabetic foot complication risk highlighted in men

Men should be considered for aggressive treatment for foot complications associated with diabetes, such as ulceration and amputation, say researchers.

8 Nov 2012

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

Aileron Therapeutics, Inc. and its collaborator Roche today announced new results of a preclinical study of its Stapled Peptide oncology drug candidate ATSP-7041, which exhibited robust efficacy in MDM2 and MDMX xenograft cancer models.

8 Nov 2012

Radiopharmaceutical Tektrotyd continues to receive interest and recognition

Physicians - attendees of the 25th Annual EANM (European Association of Nuclear Medicine) Congress (October 27-31, Milan) - expressed their continuing interest in and recognition for Tektrotyd, a radiopharmaceutical responsible for significant progress in diagnostics/therapy of neuroendocrine tumours.

8 Nov 2012

Thyroid journal publishes new ATA guidelines for management of anaplastic thyroid cancer

Anaplastic thyroid cancer is a rare form of thyroid tumor, but it is also the most deadly. Newly developed evidence-based recommendations for the diagnosis, treatment, and long-term monitoring and follow-up care of patients with this extremely aggressive form of thyroid cancer are published in Thyroid, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

8 Nov 2012

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention.

7 Nov 2012

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

Today, Bristol-Myers Squibb is pleased to welcome the decision by The National Institute for Health and Clinical Excellence (NICE) to recommend Yervoy (ipilimumab) for the treatment of previously-treated advanced (unresectable or metastatic) melanoma within the Final Appraisal Determination (FAD).

3 Nov 2012

MED1 plays a central role in mediating tamoxifen resistance in breast cancer

A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.

3 Nov 2012

Researchers discover how tamoxifen-resistant breast-cancer cells grow and proliferate

A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.

31 Oct 2012

Endocrine News and Research

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Selective targeting of neurotransmitters may allow for new medication therapies for GI conditions

Combined oral contraceptives increase risk of blood clots in women with PCOS

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

Certain occupations do increase risk of breast cancer

Cancer Network, ONCOLOGY present two part primer report on targeted therapies in solid tumors

In utero exposure to BPA associated with decreased thyroid function in newborn sheep

New study confirms neurodevelopmental effects of PBDE flame retardant exposure in children

Age at onset of first menstrual cycle associated with increased BMI, obesity in adulthood

Hearing impairment more prevalent among patients with diabetes

Diabetic foot complication risk highlighted in men

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

Radiopharmaceutical Tektrotyd continues to receive interest and recognition

Thyroid journal publishes new ATA guidelines for management of anaplastic thyroid cancer

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

MED1 plays a central role in mediating tamoxifen resistance in breast cancer

Researchers discover how tamoxifen-resistant breast-cancer cells grow and proliferate

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News